gip glp 1 drugs GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications The Effects of Dual GLP-1/GIP

Adverse Effects Aside from the debated increased risk of DR progression, a separate complication that has garnered widespread attention is the purported association of semaglutide with an increased risk of NAION, a vision-threatening condition

Elucidating the underlying cellular and molecular mechanisms could potentially usher in the development of new generations of incretin mimetics with enhanced efficacy and fewer adverse effects

Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials

These strategies offer several potential advantages over GLP-1 analogs, including a more natural stimulation of GLP-1 pathways, reduced risk of side effects, and the ability to address metabolic dysregulation at its source However, clinical applicability for pharmacological targets to increase sufficient GLP-1 production and promote L-cell differentiation has not been identified